ZA915446B - Growth hormone crystals and a process for production of these gh-crystals - Google Patents

Growth hormone crystals and a process for production of these gh-crystals

Info

Publication number
ZA915446B
ZA915446B ZA915446A ZA915446A ZA915446B ZA 915446 B ZA915446 B ZA 915446B ZA 915446 A ZA915446 A ZA 915446A ZA 915446 A ZA915446 A ZA 915446A ZA 915446 B ZA915446 B ZA 915446B
Authority
ZA
South Africa
Prior art keywords
crystals
production
growth hormone
hgh
divalent cation
Prior art date
Application number
ZA915446A
Other languages
English (en)
Inventor
Flemming Junker
Junker Flemming
Claus Friis Theisen
Friis Theisen Claus
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA915446B publication Critical patent/ZA915446B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ZA915446A 1990-07-13 1991-07-12 Growth hormone crystals and a process for production of these gh-crystals ZA915446B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK168790A DK168790D0 (xx) 1990-07-13 1990-07-13

Publications (1)

Publication Number Publication Date
ZA915446B true ZA915446B (en) 1992-03-25

Family

ID=8107212

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA915446A ZA915446B (en) 1990-07-13 1991-07-12 Growth hormone crystals and a process for production of these gh-crystals

Country Status (17)

Country Link
US (1) US6117984A (xx)
EP (1) EP0540582B1 (xx)
JP (1) JP2524446B2 (xx)
AT (1) ATE110745T1 (xx)
AU (1) AU666465B2 (xx)
BG (1) BG61267B1 (xx)
CA (1) CA2086087C (xx)
DE (1) DE69103755T2 (xx)
DK (2) DK168790D0 (xx)
ES (1) ES2060399T3 (xx)
HU (2) HUT64086A (xx)
IE (1) IE67054B1 (xx)
NZ (1) NZ238904A (xx)
PT (1) PT98297B (xx)
RU (1) RU2108341C1 (xx)
WO (1) WO1992000998A1 (xx)
ZA (1) ZA915446B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK168790D0 (xx) * 1990-07-13 1990-07-13 Novo Nordisk As
US6894023B1 (en) * 1990-07-13 2005-05-17 Novo Nordisk A/S Growth hormone crystals and a process for production of these GH-crystals
DE69232847T2 (de) * 1991-12-20 2003-09-11 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
SE9302278D0 (sv) * 1992-10-28 1993-07-02 Kabi Pharmacia Ab Growth hormone
US6197350B1 (en) 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US7101575B2 (en) 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US6451347B1 (en) 1999-03-01 2002-09-17 Alkermes Controlled Therapeutics, Inc. Method for purifying human growth hormone
JP4970678B2 (ja) * 1999-06-10 2012-07-11 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 多層コーティングによる結晶のカプセル化
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
CA2418960A1 (en) 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
CA2424896A1 (en) 2000-10-06 2002-04-11 Jagotec Ag A controlled-release, parenterally administrable microparticle preparation
SE517422C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Farmaceutiskt acceptabel stärkelse
SE517421C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
SE518007C2 (sv) 2000-11-16 2002-08-13 Bioglan Ab Förfarande för framställning av mikropartiklar
US7105181B2 (en) 2001-10-05 2006-09-12 Jagotec, Ag Microparticles
SE0201599D0 (sv) 2002-03-21 2002-05-30 Skyepharma Ab Microparticles
SE0202719D0 (sv) * 2002-09-13 2002-09-13 Pharmacia Ab Process for mfg crystals of growth hormone
CN101659701B (zh) * 2002-12-31 2019-03-26 阿尔特斯制药公司 人生长激素晶体和制备它们的方法
BR0317888A (pt) 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
BR0317896A (pt) * 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Complexos de cristais de proteìna e polìmeros iÈnicos
WO2005014034A1 (en) * 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
JP2009521486A (ja) * 2005-12-23 2009-06-04 アルタス ファーマシューティカルズ インコーポレイテッド ポリカチオン錯化タンパク質結晶を含む組成物およびこれを使用した治療法
US8071544B2 (en) 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA653324A (en) * 1962-12-04 G. Brink Norman Growth hormone and methods of preparing the same
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2174862A (en) * 1938-12-30 1939-10-03 Frederick Stearns & Company Process of producing crystalline insulin
US2595278A (en) * 1950-04-28 1952-05-06 Armour & Co Preparation of insulin from pancreas glands
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2897117A (en) * 1955-02-10 1959-07-28 Univ Alberta Insulin process
US3856771A (en) * 1973-07-16 1974-12-24 Lilly Co Eli Process for manufacturing alkali metal or ammonium insulin
EP0343696B1 (en) * 1984-10-04 1996-01-03 Monsanto Company Zinc-associated somatotropins
HU196714B (en) * 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IL79681A (en) * 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
EP0277043A3 (en) * 1987-01-30 1989-08-23 IMCERA Group Inc. Method for recovering somatotropins from dilute aqueous solution
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE68929273T2 (de) * 1988-08-24 2001-07-05 American Cyanamid Co Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
US5109117A (en) * 1990-06-26 1992-04-28 Monsanto Company Method of somatotropin naturation using urea and a soluble organic alcohol
DK168790D0 (xx) * 1990-07-13 1990-07-13 Novo Nordisk As
US5780599A (en) * 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals

Also Published As

Publication number Publication date
ATE110745T1 (de) 1994-09-15
AU666465B2 (en) 1996-02-15
PT98297B (pt) 1999-01-29
HUT64086A (en) 1993-11-29
US6117984A (en) 2000-09-12
BG97281A (bg) 1994-03-24
JPH05507497A (ja) 1993-10-28
DE69103755T2 (de) 1995-02-23
HU210323B (en) 1995-03-28
DK168790D0 (xx) 1990-07-13
EP0540582B1 (en) 1994-08-31
EP0540582A1 (en) 1993-05-12
AU8284691A (en) 1992-02-04
NZ238904A (en) 1993-04-28
HU9300067D0 (en) 1993-04-28
IE912444A1 (en) 1992-01-15
CA2086087C (en) 1999-09-14
RU2108341C1 (ru) 1998-04-10
JP2524446B2 (ja) 1996-08-14
IE67054B1 (en) 1996-02-21
BG61267B1 (en) 1997-04-30
ES2060399T3 (es) 1994-11-16
CA2086087A1 (en) 1992-01-14
DE69103755D1 (de) 1994-10-06
WO1992000998A1 (en) 1992-01-23
DK0540582T3 (da) 1995-01-30
PT98297A (pt) 1992-05-29

Similar Documents

Publication Publication Date Title
ZA915446B (en) Growth hormone crystals and a process for production of these gh-crystals
YU101385A (en) Process for obtaining crystal calcium pseudomonate or its hydrate
HU893408D0 (en) Process for the production of glycosamino-glucane salts and medical preparations containing them
NZ228632A (en) Topical otopathic preparations containing ofloxacin
GB8828694D0 (en) Preparation for introducing active substance for regulating tanning into skin production & use thereof
HUT51596A (en) Process for production of the active substance of the medical composition levodopa
HU911443D0 (en) Process for the production of medical preparations containing pravastaine and fibrinous-acid derivatives
AU1474788A (en) Crystalline human proinsulin and process for its production
HU908361D0 (en) Process for the production of oxazole derivatives and medical preparations containing them as active agents
DE3572441D1 (en) Use of interferon gamma (ifn-gamma) for the production of preparations for treating rheumatic diseases
HU912213D0 (en) Process for the production of amino-diol derivatives and medical preparations containing them
GB8804068D0 (en) Improvements relating to control of neoplastic tissue growth
HU912287D0 (en) Process for the production of sulphur-substituted mevin acid derivatives and medical preparations containing them
HU9200230D0 (en) Process for the production of 3-amino-sidnonimine derivatives and medical preparations containing them
EP0219295A3 (en) Process for producing human growth hormone
HU9201483D0 (en) Process for the production of 1h-rh-analogues'acid additive salts, and for the production of medical preparations containing them
HU913159D0 (en) Process for the production of 3-piperazino-sydnonymine derivatives and medical preparations containing them
HU9200116D0 (en) Process for the production of novel kinoline-8-carbonic acid derivatives and medical preparations containing them
HU9200456D0 (en) Process for the production of medical preparations containing pteridine derivatives
HU9201487D0 (en) Process for the production of pirimidine derivatives and of medical preparations containing them
HU908316D0 (en) Process for the production of medical preparations containing new amino-acid derivatives with medicative effect
BG42195A1 (en) Growth regulator of cotton
BG40975A1 (en) Nutritive solution for hydroponous cultivating of carnations